Wechselwirkungen · Triumeq
Triumeq 50 mg/600 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12–13
HOS-129269 · Präparat HOS-096703
12 phosphorylation of cladribine leading to a potential risk of cladribine loss of efficacy in case of combination in the clinical setting. Some clinical findings also support a possible interaction between lamivudine and cladribine Opioids Methadone/Abacavir Abacavir: Methadone dose adjustment likely not (40 to 90mg once daily for 14 AUC ↔ needed in majority of patients; days/600mg single dose, then Cmax ↓35% occasionally methadone re-titration may 600mg twice daily for 14 days) be required. Methadone: CL/F ↑22% Retinoids Retinoid compounds Interaction not studied Insufficient data to recommend dose (e.g. Isotretinoin) adjustment. Possible interaction given common pathway of elimination via alcohol dehydrogenase (abacavir- component). Miscellaneous Alcohol Ethanol/Dolutegravir Interaction not studied No dose adjustment necessary. Ethanol/Lamivudine (Inhibition of alcohol dehydrogenase)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198) isotretinoin (HOS-108570) ethanol (HOS-089988) cladribine (HOS-085842)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T14:46:00Z · SHA-256 b49ac3bee235cd6ac4023cc2bbeb8b80e01234448e4e420209ba281a1edf7209 · Passage b1628c72c158b964dea3d515c6c762ac282af33315bd89f852898764f5f5550e · Zeichen 20703–22495 im Abschnitt